1-5 of 5
Georg Karpel-Massler
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Induction of Synthetic Lethality by Activation of Mitochondrial ClpP and Inhibition of HDAC1/2 in Glioblastoma

Open Access
Trang T.T. Nguyen, Enyuan Shang, Salveena Schiffgens, Consuelo Torrini, Chang Shu, Hasan Orhan Akman, Varun V. Prabhu, Joshua E. Allen, Mike-Andrew Westhoff, Georg Karpel-Massler, Markus D. Siegelin
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (9): 1881–1895.
https://doi.org/10.1158/1078-0432.CCR-21-2857
Published: 02 May 2022
View articletitled, Induction of Synthetic Lethality by Activation of Mitochondrial ClpP and Inhibition of HDAC1/2 in Glioblastoma
Open the PDF for Induction of Synthetic Lethality by Activation of Mitochondrial ClpP and Inhibition of HDAC1/2 in Glioblastoma in another window
Includes: Supplementary data
Journal Articles

Metabolic Reprogramming by Dual AKT/ERK Inhibition through Imipridones Elicits Unique Vulnerabilities in Glioblastoma

Free
Chiaki T. Ishida, Yiru Zhang, Elena Bianchetti, Chang Shu, Trang T.T. Nguyen, Giulio Kleiner, Maria J. Sanchez-Quintero, Catarina M. Quinzii, Mike-Andrew Westhoff, Georg Karpel-Massler, Varun V. Prabhu, Joshua E. Allen, Markus D. Siegelin
Journal: Clinical Cancer Research
Clin Cancer Res (2018) 24 (21): 5392–5406.
https://doi.org/10.1158/1078-0432.CCR-18-1040
Published: 01 November 2018
View articletitled, Metabolic Reprogramming by Dual AKT/ERK Inhibition through Imipridones Elicits Unique Vulnerabilities in Glioblastoma
Open the PDF for Metabolic Reprogramming by Dual AKT/ERK Inhibition through Imipridones Elicits Unique Vulnerabilities in Glioblastoma in another window
Includes: Supplementary data
Journal Articles

Combined HDAC and Bromodomain Protein Inhibition Reprograms Tumor Cell Metabolism and Elicits Synthetic Lethality in Glioblastoma

Free
Yiru Zhang, Chiaki Tsuge Ishida, Wataru Ishida, Sheng-Fu L. Lo, Junfei Zhao, Chang Shu, Elena Bianchetti, Giulio Kleiner, Maria J. Sanchez-Quintero, Catarina M. Quinzii, Mike-Andrew Westhoff, Georg Karpel-Massler, Peter Canoll, Markus D. Siegelin
Journal: Clinical Cancer Research
Clin Cancer Res (2018) 24 (16): 3941–3954.
https://doi.org/10.1158/1078-0432.CCR-18-0260
Published: 14 August 2018
View articletitled, Combined HDAC and Bromodomain Protein Inhibition Reprograms Tumor Cell Metabolism and Elicits Synthetic Lethality in Glioblastoma
Open the PDF for Combined HDAC and Bromodomain Protein Inhibition Reprograms Tumor Cell Metabolism and Elicits Synthetic Lethality in Glioblastoma in another window
Includes: Supplementary data
Journal Articles

A Synthetic Cell-Penetrating Dominant-Negative ATF5 Peptide Exerts Anticancer Activity against a Broad Spectrum of Treatment-Resistant Cancers

Free
Georg Karpel-Massler, Basil A. Horst, Chang Shu, Lily Chau, Takashi Tsujiuchi, Jeffrey N. Bruce, Peter Canoll, Lloyd A. Greene, James M. Angelastro, Markus D. Siegelin
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (18): 4698–4711.
https://doi.org/10.1158/1078-0432.CCR-15-2827
Published: 15 September 2016
View articletitled, A Synthetic Cell-Penetrating Dominant-Negative ATF5 Peptide Exerts Anticancer Activity against a Broad Spectrum of Treatment-Resistant Cancers
Open the PDF for A Synthetic Cell-Penetrating Dominant-Negative ATF5 Peptide Exerts Anticancer Activity against a Broad Spectrum of Treatment-Resistant Cancers in another window
Includes: Supplementary data
Journal Articles

Bortezomib Primes Glioblastoma, Including Glioblastoma Stem Cells, for TRAIL by Increasing tBid Stability and Mitochondrial Apoptosis

Free
Thomas Unterkircher, Silvia Cristofanon, Sri Hari Krishna Vellanki, Lisa Nonnenmacher, Georg Karpel-Massler, Christian Rainer Wirtz, Klaus-Michael Debatin, Simone Fulda
Journal: Clinical Cancer Research
Clin Cancer Res (2011) 17 (12): 4019–4030.
https://doi.org/10.1158/1078-0432.CCR-11-0075
Published: 15 June 2011
View articletitled, Bortezomib Primes Glioblastoma, Including Glioblastoma Stem Cells, for TRAIL by Increasing tBid Stability and Mitochondrial Apoptosis
Open the PDF for Bortezomib Primes Glioblastoma, Including Glioblastoma Stem Cells, for TRAIL by Increasing tBid Stability and Mitochondrial Apoptosis in another window